anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
Currently, medical professionals obtain respiratory rate for vital signs assessments either by counting the number of breaths during a 15, 30, or 60 second interval and multiplying to obtain breaths per minute, or by reading the respiratory rate off of a multiparameter vital signs monitor (such as a Welch Allyn Propaq Monitor), that provides respiratory effort information based on the change of AC impedance through ECG leads. The Respiration channel (RESP) of the Welch Allyn Propaq is intended to detect the rate or absence of respiratory effort, deriving the signal by measuring the AC impedance between the selected terminals of the ECG electrodes. The RSpot 100 Non-Contact Respiratory Rate Spot Check provides an alternative to the medical professional counting respiratory rate or reading the rate from a vital signs monitor designed for continuous respiratory rate monitoring. The Kai Sensors RSpot 100 Non-Contact Respiratory Rate Spot Check is used for a one-time measurement of respiratory rate as part of a vital signs assessment in the hospital or other clinical settings.

In this study, the RSpot is operated simultaneously with two other systems that provide a respiratory rate: Welch Allyn Propaq Encore model 242 and Embletta system with Universal XactTrace and Somnologica software. A respiratory rate is also obtained by counting respiratory excursions for the same duration as the RSpot measurement interval, 15, 30, or 60 seconds. The rates obtained from each of the four measurement methods are then compared.
The study envisages the voluntary enrollment of healthy subjects, referring to treatment clinics for work-related pathologies (excluding subjects aged \<18 or \> 65 years, and those with musculoskeletal pathologies or other disabling pathologies in progress), to carry out two repeated lifting tests. The two tests are set up to correspond respectively to the two NIOSH risk classes (LI\<1, NO RISK; and LI\>1, RISK). The IMU sensors provide wirelessly a series of data from which it is intended to extract a number of features (feature extraction) that have a high predictive power, through the digital signal processing technique using dedicated software (i.e. Matlab, SPSS). In a second step, data obtained from EMG sensors will be added to the analysis. Among the different artificial intelligence algorithms, the investigator will look for those most able to discriminate the various risk classes on the basis of the parameters extracted from the signals detected during the motor task.
BACKGROUND: Managing risk effectively within small animal veterinary practice is integral for staff, patient and client safety. Veterinary personnel are exposed to many risks, including bites, scratches, sharps injuries and exposure to zoonotic diseases and multi-resistant organisms. Patients may also be exposed to healthcare-associated infections, including multi-resistant organisms. While veterinary owners/managers have a duty of care under legislated Workplace Health and Safety requirements, all staff have a responsibility to contribute to assessing and minimizing risk. The application of standard and transmission precautions will help with risk minimization. This study aimed to determine how small animal veterinary staff understand and perceive infection prevention and control risk and to provide recommendations to assist with risk mitigation.
METHODS: A mixed methods design was used. A digital questionnaire was administered to small animal veterinary staff in Australia to identify knowledge, attitudes and practices of risk related behaviors. Follow up focus groups were conducted with small animal practitioners to explore factors supporting and preventing veterinary staff from implementing recommended practices identified in the questionnaire.
RESULTS: Small animal veterinary staff acknowledged they participated in many high-risk activities, including recapping needles and eating and drinking in patient care areas. Injuries were common, with 77% of staff receiving a bite or scratch, and 22% receiving a sharps injury in the preceding six months. Less than one in five of these incidents was reported. Staff agreed effective infection prevention and control was the responsibility of all staff, but a designated staff member should take responsibility for managing it. The practice owner/manager was integral to supporting and promoting recommended strategies, contributing to a positive workplace culture and improving safety for staff and patients.
CONCLUSION: Small animal veterinary staff have some understanding of how to identify, report, manage and mitigate risk but were limited by their knowledge of infection prevention and control principles.
This study aims to compare novel designs to products currently in the marketplace by comparing scores on a survey tool which measures comfort and tolerability of respiratory protective devices. Study participants will be clinical healthcare workers who have experience wearing respiratory protective devices in their workplace. We will enroll up to 400 participants in the study, made up of physicians, nurses, nursing assistants and other healthcare employees who have previously been fit-tested to a N95 respirator. Subjects will be screened to determine eligibility and must pass fit-testing on the respirator he/she is randomized to. Participants will wear the respirator while performing a series of motions that simulate movements made by healthcare workers when performing patient care tasks. There will be no contact with patients during participation. Feedback via validated survey tool will be collected from all study participants on the comfort and tolerability of the respirator worn.
PURPOSE: The minimal important change (MIC) is defined as the smallest within-individual change in a patient-reported outcome measure (PROM) that patients on average perceive as important. We describe a method to estimate this value based on longitudinal confirmatory factor analysis (LCFA). The method is evaluated and compared with a recently published method based on longitudinal item response theory (LIRT) in simulated and real data. We also examined the effect of sample size on bias and precision of the estimate.
METHODS: We simulated 108 samples with various characteristics in which the true MIC was simulated as the mean of individual MICs, and estimated MICs based on LCFA and LIRT. Additionally, both MICs were estimated in existing PROMIS Pain Behavior data from 909 patients. In another set of 3888 simulated samples with sample sizes of 125, 250, 500, and 1000, we estimated LCFA-based MICs.
RESULTS: The MIC was equally well recovered with the LCFA-method as using the LIRT-method, but the LCFA analyses were more than 50 times faster. In the Pain Behavior data (with higher scores indicating more pain behavior), an LCFA-based MIC for improvement was estimated to be 2.85 points (on a simple sum scale ranging 14-42), whereas the LIRT-based MIC was estimated to be 2.60. The sample size simulations showed that smaller sample sizes decreased the precision of the LCFA-based MIC and increased the risk of model non-convergence.
CONCLUSION: The MIC can accurately be estimated using LCFA, but sample sizes need to be preferably greater than 125.
The present invention belongs to the technical field of medicinal preparation. The present invention provides an optical pure S-(-)-and R-(+)-omeprazole preparation and a preparation method. Proper amount of alkaline substances are added in the prepration of the present invention, such as sodium hydroxide, magnesium hydroxide, sodium phosphate, sodium carbonate, etc. so as to keep the pH value larger than 9. A certain amount of stabilizing agent is added, such as sodium sulfite, sodium thiosulfate, etc. By specific preparation methods, such as inert gas granulation, coating, drying, etc., the preparation maintains corresponding stable appearance characteristics and stable optical purity in the process of processing, storage and transportation. The preparations prepared by the present invention, such as tablets, capsule, injection, etc., are more suitable for oral application and non-intestinal tract administration so as to attain the purpose of active component treatment. The present invention has the advantages of simple process, good product stability and high finished product rate, and the solvent used in the method has no toxicity and is suitable for industrial production.
A carton (105) for cooperating with a packaging material (M) to contain a plurality of articles (C) and a package formed thereby. The carton comprises a plurality of panels comprising a central panel (110), a first side panel (120), and a second side panel (140). The side panels are positioned relative to the central panel to at least partially form a space for receiving the articles. A handle (111) is formed in at least one of the side panels. The handle is adapted for grasping and carrying the carton. A reinforcement flap (126,128) is foldably attached to the at least one of the side panels for positioning relative to the at least one side panel for contacting the articles to secure the carton to the articles.
NK cells are isolated from healthy donors through the apheresis process and subsequently separated using the CLINIMACS device in a clean room environment. After quality assessment (sterility, viable cell count, purity, and phenotype of active cells), they are stored at -198°C until use. Upon need, the cells are thawed and washed, followed by checking their viability, count, and sterility. Children between the ages of 2 to 16 who meet the eligibility criteria will be added to the study. After admission, the cells are injected into the patient at a ratio of 5×10\^6 cells per kilogram of the patient's body weight. A total of 3 injections are administered to all patients. Based on the patient's response and recovery status, the need for additional injections is evaluated. If improvements in the patient's condition are observed after the last injection and confirmed by MRI MIBG, further 2 injections can continue. The intervals between injections vary based on the patient's standard treatment, and the cells are injected 10 days after the completion of each chemotherapy course.
PURPOSE:A carcinostatic agent, capable of acting on the linking part of phosphoric acid, e.g. adenosine-4-phosphate or adnosine-5-phosphate, etc. which is an acid link of high energy in cancerous cells severing the linking part of the adenosine-3-phosphate, etc. without damaging the normal cells. CONSTITUTION:A carcinostatic agent, capable of acting on the linking part of phosphoric acid in adenosine-40-phosphate (A4P), adenosine-5-phosphate (A5P) or adenosine-6-phosphate (A6P) which is an acid link of high energy in cancerous cells, and severing the linking part thereof with the adenosine-3-phosphate (ATP) or further the respective linking parts of the phosphoric acid with higher energy without acting on the linking parts of the phosphoric acid in ATP, ADP and AMP of the normal cells having no phosphoric acid linkages with higher energy than the ATP. The cencerous cells are constituted of phosphoric acid linkages of high energy, and the linking parts of phosphoric acid in A4P, A5P and A6P are severed to reduce the energy metabolic ability of the cancerous cells. Therefore, the phosphoric acid linking parts of high energy other than adenosine cannot remain and return to the normal ATP.
Clinical studies of desmopressin nasal spray solution 0.01% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.  
  
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Desmopressin nasal spray solution 0.01% is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min). (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics and CONTRAINDICATIONS.)  
  
Use of desmopressin nasal spray solution 0.01% in geriatric patients will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. (See WARNINGS).   
  
There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.
COH will be performed by using a long GnRH agonist protocol as previous described or using a flexible GnRH antagonist protocol. During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH (luteinizing hormone) suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
Due to physiologic and immune changes, pregnant women are at high risk of severe complications and mortality from COVID-19 infections. Despite this, epidemiologic data on SARS-CoV-2 infection in pregnancy is currently limited to small case-series describing a clinical course ranging from mild to critical illness requiring extracorporeal membrane oxygenation. Chloroquine and hydroxychloroquine (HCQ) have demonstrated activity against SARS-coronaviruses in laboratory studies and are being tested in COVID-19 positive patients. HCQ appears more promising than chloroquine due to its greater effectiveness against SARS-CoV-2 in vitro and better safety profile. To date, pregnant women have been systematically excluded from trials conducted in the general outpatient population. Thus, we will carry out a randomized, placebo-controlled, double blinded trial of HCQ (considered safe in pregnancy in pregnant women with early COVID-19 infection across Canada to evaluate its effect in reducing COVID-19-related hospitalizations. This outpatient intervention is of paramount importance as its goal is to avoid overloading emergency rooms, obstetric triage, inpatient wards and critical care units. Upon completion of 6-month, our results can be directly applied to clinical care.
A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
A monitoring device for maintenance prediction for a medical imaging apparatus and a related method are described. First and second data sets of parameters of the medical imaging apparatus are measured over respective first and second periods by a data processing unit, one data set for each period. The second data set comprises data samples selected based on a trigger point. Operation modes of the medical imaging apparatus are identified based on the first set and the selected data samples. It is analysed whether there are corresponding operation modes, one operation mode for each data set. In a validation step it is validated whether the measured parameters in the first set and the selected data samples differ. Based on the outcome of the validation step, a feedback signal is issued, including maintenance prediction information.
PURPOSE:To provide a novel compound having an action for stimulating the secretion of a pulmonary surface-activating substance, and useful as an expectorant and a respiratory organ disease therapeutic agent. CONSTITUTION:A compound of formula I (R1-R5 are H, lower alkoxy) or its acid adduct, e.g. 2-(2,3,4-trimethoxybenzyl)-2-azabicyclo [2,2,2] octane hydrochloride. The compound of formula I is obtained by reacting 2- azabicyclo[2,2,2]octane hydrochloride of formula II with a halogen compound of formula III (X is halogen) in the presence of a base (e.g. potassium carbonate) in a solvent (e.g. DMF) at room temperature. The compound of formula I is useful for the therapy of respiratory organ diseases such as neonatal respiratory distress syndromes, adult respiratory distress syndromes, pulmonary edema, acute or chronic respiratory insufficiency, bronchitis, various infectious diseases, and asthma.
PURPOSE: The optimal duration of antibiotic therapy for fracture-related infection (FRI) has not been well defined. Our aim was to assess the recurrence rate of infection in patients who underwent six, 12, or 24 weeks of antibiotic therapy following surgical treatment for FRI one year after antibiotic discontinuation. Additionally, complications were monitored.
METHODS: Patients with FRI underwent surgical treatment, and antibiotic therapy was initiated. The patients were divided into groups at the 6th and 12th weeks of antibiotic therapy. The primary endpoint was the recurrence of deep or superficial infection at 90 days and one year after the end of antimicrobial therapy.
RESULTS: There was no difference in the recurrence of infection 90 days or one year after stopping antibiotic therapy among patients treated for six, 12, or 24 weeks (p = 0.98 and p = 0.19, respectively). The overall recurrence rate of infection 90 days after stopping antibiotic therapy was 4.9% (8/163), and one year after discontinuation of antibiotic therapy was 9.8% (16/163). There was a statistically significant difference in the incidence of adverse effects among the three groups (chi-square; p = 0.01). Adverse effects were more common in the group treated for 24 weeks than in the groups treated for 6 weeks (z score, p = 0.017) or 12 weeks (z score, p = 0.005).
CONCLUSION: Antibiotic therapy longer than 6 weeks did not reduce the recurrence of FRI after one year of follow-up. Additionally, antibiotic treatment for 24 weeks increases adverse events such as skin reactions and acute renal failure.
The invention discloses application of Gypensapogenin B in preparing a medicine for treating atherosclerosis. Gypensapogenin B can play the function of resisting atherosclerosis by adjusting blood fat and protecting endothelial cells. The medicine for treating atherosclerosis, which is prepared by Gypensapogenin B, has favorable curative effect on resisting atherosclerosis, and can be used for resisting atherosclerosis of human or animals. The application of Gypensapogenin B in preparing the medicine for resisting atherosclerosis, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the atherosclerosis resisting activity of Gypensapogenin B is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin B has outstanding actual characteristics. Meanwhile, Gypensapogenin B has outstanding progress when being used for resisting atherosclerosis.
The invention discloses traditional Chinese medicine for treating adult varicella and a preparation method thereof. The traditional Chinese medicine is prepared from herb of ajuga macrosperma Wall. Ex Benth., roots, branches and leaves of viburnum dilatatum Thunb., roots or root bark of celasturs angulatus maxim, herb of polygonum barbatum L., herb of aster ageratoides Turcz., herba boenninghauseniae, fruit of carex baccans Nees., roots and branch leaves of embelia laeta (L.), herb of aopecurus aequalis Sobol., seeds of amaranthus caudatus L., herb of colona floribunda (Wall.) Craib., herb of oreocnide frutescens (Thunb.)Miq., herb of synedrella nodiflora (L.)Gaertn., rhizomes and roots of dysosma difformis (Hemsl. et Wils.) T. H. Wang, bulbs of gladiolus gandavensis van houtte, bulbs, leaves and seeds of brassica caulorapa Pasq. herb of Indian pentanema and herb of nymphoides peltatum (Gmel.)Kuntze. The traditional Chinese medicine has the advantages of being convenient to administrate, easy to prepare, low in cost, capable of treating the adult varicella by combining conventional western medicine, better in treatment effect, higher in cure rate and free of toxic and side effects and adverse effects.
Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
The invention discloses a Ganoderma applanatum composition for enhancing immune function and a preparation method thereof, relates to the field of traditional Chinese medicines, aims to provide a method for refining and fully utilizing traditional Chinese medicine resources aiming at the defects in the prior art, and provides a composition for enhancing immune function, a preparation method and application thereof. Thereby improving the utilization rate and the economic value of the lingua, the sea buckthorn and the garlic. Polysaccharides in the Ganoderma Applanatum extract, flavones in the fructus Hippophae extract, and garlicin in the Bulbus Allii extract have synergistic effect, and can enhance human immunity. The three articles are food and medicine, and are safe and effective to use. Solves the problem of large toxic and side effects of the chemicals for enhancing immunity. The invention is applied to the field of medicine preparation.
INTRODUCTION: Anxiety, nausea and vomiting are common side effects suffered by paediatric patients receiving chemotherapy. Emerging evidence supports the efficacy of immersive virtual reality (IVR) on improving anxiety and distress symptoms including nausea and vomiting in this vulnerable group. This trial aims to evaluate the effects of IVR intervention on anxiety, chemotherapy-induced nausea and vomiting and anticipatory nausea and vomiting in patients with paediatric cancer receiving first chemotherapy.
METHOD AND ANALYSIS: An assessor-blinded, randomised controlled trial with a mixed methods evaluation approach. On the basis of our pilot results, 128 chemotherapy-naive patients with paediatric cancer scheduled to receive their first intravenous chemotherapy will be recruited from a public hospital and randomly allocated to intervention (n=64) or control groups (n=64). The intervention group will receive the IVR intervention for three sessions: 2 hours before the first chemotherapy, 5 min before and during their first chemotherapy and 5 min before and during their second chemotherapy, respectively. The control group will receive standard care only. A subsample of 30 participants in the intervention group will be invited for a qualitative interview. Study instruments are: (1) short form of the Chinese version of the State Anxiety Scale for Children, (2) visual analogue scale for anticipatory nausea and vomiting, (3) Chinese version of the Multinational Association of Supportive Care in Cancer Antiemesis Tool and (4) individual face-to-face semistructured interviews to explore intervention participants' perceptions of the IVR intervention.
ETHICS AND DISSEMINATION: This study has been approved by the Hong Kong Children's Hospital Research Ethics Committee (HKCH-REC-2021-009). The findings will be disseminated in peer-reviewed journals and through local or interventional conference presentations.
TRIAL REGISTRATION NUMBER: ChiCTR2100048732.